Angiotensin II-like immunoreactivity in human ovarian follicular fluid. 1986

M D Culler, and B C Tarlatzis, and A Lightman, and L A Fernandez, and A H Decherney, and A Negro-Vilar, and F Naftolin

Human ovarian follicular fluid (hFF) has angiogenic activity, although the causative factors are unknown. We recently found that hFF contains renin activity which converts renin substrate to angiotensin I (AI). Since the enzymatic cleavage product of AI, angiotensin II (AII), is a potent stimulator of new vessel formation, we have examined Sephadex G-25 column fractions of hFF and extracted hFF and plasma from individual patients for AII-like immunoreactivity (AII-IR). Eluent fractions from Sephadex G-25 column chromatography of hFF had significant AII-IR which eluted in the same fractions as synthetic AII. Individual, extracted FF samples contained approximately 10 times higher levels of AII-IR than extracts of plasma from the same patients. Serial dilutions of the Sephadex column fractions and extracted FF and plasma inhibited binding of 125I-AII to rabbit anti-AII serum in a manner parallel to the inhibition caused by synthetic AII, indicating that the detected immunoreactivity was not due to non-specific assay interference. In summary, the results indicate the presence of significant AII-like immunoreactivity in hFF. AII may now be considered as a potential mediator of the angiogenic activity present in hFF and may play an important paracrine and/or autocrine role in physiologic events in the ovary.

UI MeSH Term Description Entries
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D001826 Body Fluids Liquid components of living organisms. Body Fluid,Fluid, Body,Fluids, Body
D005260 Female Females
D006080 Ovarian Follicle An OOCYTE-containing structure in the cortex of the OVARY. The oocyte is enclosed by a layer of GRANULOSA CELLS providing a nourishing microenvironment (FOLLICULAR FLUID). The number and size of follicles vary depending on the age and reproductive state of the female. The growing follicles are divided into five stages: primary, secondary, tertiary, Graafian, and atretic. Follicular growth and steroidogenesis depend on the presence of GONADOTROPINS. Graafian Follicle,Atretic Follicle,Ovarian Follicles,Atretic Follicles,Follicle, Atretic,Follicle, Graafian,Follicle, Ovarian,Follicles, Atretic,Follicles, Graafian,Follicles, Ovarian,Graafian Follicles
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine

Related Publications

M D Culler, and B C Tarlatzis, and A Lightman, and L A Fernandez, and A H Decherney, and A Negro-Vilar, and F Naftolin
January 1996, Peptides,
M D Culler, and B C Tarlatzis, and A Lightman, and L A Fernandez, and A H Decherney, and A Negro-Vilar, and F Naftolin
January 1991, Hormone research,
M D Culler, and B C Tarlatzis, and A Lightman, and L A Fernandez, and A H Decherney, and A Negro-Vilar, and F Naftolin
April 1978, Klinische Wochenschrift,
M D Culler, and B C Tarlatzis, and A Lightman, and L A Fernandez, and A H Decherney, and A Negro-Vilar, and F Naftolin
January 1981, Brain research,
M D Culler, and B C Tarlatzis, and A Lightman, and L A Fernandez, and A H Decherney, and A Negro-Vilar, and F Naftolin
August 1985, Fertility and sterility,
M D Culler, and B C Tarlatzis, and A Lightman, and L A Fernandez, and A H Decherney, and A Negro-Vilar, and F Naftolin
December 1986, Human reproduction (Oxford, England),
M D Culler, and B C Tarlatzis, and A Lightman, and L A Fernandez, and A H Decherney, and A Negro-Vilar, and F Naftolin
January 1991, Gynecologic and obstetric investigation,
M D Culler, and B C Tarlatzis, and A Lightman, and L A Fernandez, and A H Decherney, and A Negro-Vilar, and F Naftolin
March 1995, Fertility and sterility,
M D Culler, and B C Tarlatzis, and A Lightman, and L A Fernandez, and A H Decherney, and A Negro-Vilar, and F Naftolin
September 1989, Molecular and cellular endocrinology,
M D Culler, and B C Tarlatzis, and A Lightman, and L A Fernandez, and A H Decherney, and A Negro-Vilar, and F Naftolin
October 1981, Brain research,
Copied contents to your clipboard!